WO2000061183A3 - Methodes de traitement de lymphomes par la verotoxine - Google Patents

Methodes de traitement de lymphomes par la verotoxine Download PDF

Info

Publication number
WO2000061183A3
WO2000061183A3 PCT/CA2000/000371 CA0000371W WO0061183A3 WO 2000061183 A3 WO2000061183 A3 WO 2000061183A3 CA 0000371 W CA0000371 W CA 0000371W WO 0061183 A3 WO0061183 A3 WO 0061183A3
Authority
WO
WIPO (PCT)
Prior art keywords
verotoxin
lymphomas
treatment
lymphoma
ptld
Prior art date
Application number
PCT/CA2000/000371
Other languages
English (en)
Other versions
WO2000061183A2 (fr
Inventor
Clifford A Lingwood
Gerald Arbus
Original Assignee
Hsc Res Dev Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hsc Res Dev Lp filed Critical Hsc Res Dev Lp
Priority to AU37985/00A priority Critical patent/AU3798500A/en
Publication of WO2000061183A2 publication Critical patent/WO2000061183A2/fr
Publication of WO2000061183A3 publication Critical patent/WO2000061183A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des méthodes de traitement du lymphome par l'administration d'un agent fixant le Gb3. Dans un mode de réalisation le lymphome peut être une affection lymphoproliférative après greffe.
PCT/CA2000/000371 1999-04-09 2000-04-07 Methodes de traitement de lymphomes par la verotoxine WO2000061183A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU37985/00A AU3798500A (en) 1999-04-09 2000-04-07 Verotoxin treatment of lymphomas

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12867099P 1999-04-09 1999-04-09
US60/128,670 1999-04-09

Publications (2)

Publication Number Publication Date
WO2000061183A2 WO2000061183A2 (fr) 2000-10-19
WO2000061183A3 true WO2000061183A3 (fr) 2001-02-08

Family

ID=22436415

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2000/000371 WO2000061183A2 (fr) 1999-04-09 2000-04-07 Methodes de traitement de lymphomes par la verotoxine

Country Status (2)

Country Link
AU (1) AU3798500A (fr)
WO (1) WO2000061183A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100335900C (zh) * 2001-11-30 2007-09-05 加拿大国家研究局 新的自组装分子
EP1386927B1 (fr) 2002-08-02 2005-03-30 Institut Curie Shiga Toxine subunité B comme une vecteur pour la diagnose des tumeurs et pour l'administration aux tumeurs exprimants GB3

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0130132A1 (fr) * 1983-06-27 1985-01-02 Etablissement Public dit: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) Immunotoxine antitumorale, préparations pharmaceutiques la contenant et son utilisation in vitro
WO1995022349A1 (fr) * 1994-02-22 1995-08-24 Geva, Ruth Compositions pharmaceutiques de verotoxines et traitements medicaux utilisant ces compositions
WO1998051326A1 (fr) * 1997-05-16 1998-11-19 Hsc Research And Development Limited Partnership Inhibition de l'angiogenese au moyen de verotoxines

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0130132A1 (fr) * 1983-06-27 1985-01-02 Etablissement Public dit: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) Immunotoxine antitumorale, préparations pharmaceutiques la contenant et son utilisation in vitro
WO1995022349A1 (fr) * 1994-02-22 1995-08-24 Geva, Ruth Compositions pharmaceutiques de verotoxines et traitements medicaux utilisant ces compositions
WO1998051326A1 (fr) * 1997-05-16 1998-11-19 Hsc Research And Development Limited Partnership Inhibition de l'angiogenese au moyen de verotoxines

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ARBUS GERALD S ET AL: "Verotoxin targets lymphoma infiltrates of patients with post-transplant lymphoproliferative disease.", LEUKEMIA RESEARCH, vol. 24, no. 10, October 2000 (2000-10-01), pages 857 - 864, XP000960973, ISSN: 0145-2126 *
LACASSE E C ET AL: "SHIGA-LIKE TOXIN PURGES HUMAN LYMPHOMA FROM BONE MARROW OF SEVERE COMBINED IMMUNODEFICIENT MICE", BLOOD,US,W.B. SAUNDERS, PHILADELPHIA, VA, vol. 88, no. 5, 1 September 1996 (1996-09-01), pages 1561 - 1567, XP000673518, ISSN: 0006-4971 *
MANGENEY MARIANNE ET AL: "Apoptosis induced in Burkitt's lymphoma cells via Gb3/CD77, a glycolipid antigen.", CANCER RESEARCH, vol. 53, no. 21, 1993, pages 5314 - 5319, XP002030860, ISSN: 0008-5472 *
RANDHAWA P S ET AL: "Morphologic and immunophenotype characterization of a cell line derived from liver tissue with Epstein-Barr virus associated post-transplant lymphoproliferative disease.", IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY ANIMAL, vol. 30A, no. 6, 1994, pages 400 - 406, XP000960975, ISSN: 1071-2690 *

Also Published As

Publication number Publication date
AU3798500A (en) 2000-11-14
WO2000061183A2 (fr) 2000-10-19

Similar Documents

Publication Publication Date Title
IL147618A0 (en) Method for treating chronic pain using mek inhibitors
PL352021A1 (en) Agent having advantageous effect on ketose
PT1355889E (pt) Derivados diamina triazole substituidos como inibidores de cinase
CA2376596A1 (fr) Anticorps anti-erbb2 humanises et traitement a l'aide de ces anticorps
BE2013C064I2 (fr)
EP2230254A3 (fr) Combinaisons thérapeutiques d'anticorps anti-igfr1
IL138724A0 (en) Transluminal device, systems and methods for enlarging interstitial penetration tracts
BR0207378A (pt) Tratamento de câncer
EP0781136A4 (fr) Composes et procedes de traitement du cancer
GB2352395A (en) Paroxetine methanesulfonate
AU5540400A (en) Bicyclic polyaminoacid metal complexes, method for preparing same and use in medical imaging
AU2003297318A1 (en) Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476.
HK1121936A1 (en) Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
HK1043603A1 (en) Hard surface treating agent, stain-proofing agent and method for surface treatment.
AU2158601A (en) Antiviral agent for use in treatment of cancer
WO2002055530A3 (fr) Conjugues de fixation au recepteur de transcobalamine utiles pour le traitement d'une proliferation cellulaire anormale
MXPA01010988A (es) Uso de un compuesto macrolido para el tratamiento del ojo seco.
WO2003082926A3 (fr) Conjugues de polymere antimicrobiens
UA83022C2 (uk) Аплідин для комбінованої терапії лейкозу та лімфоми
WO2000061183A3 (fr) Methodes de traitement de lymphomes par la verotoxine
IL161600A0 (en) Compounds and method for the treatment of over-active bladder
AU4937499A (en) Use of succinic acid or salts thereof and method of treating insulin resistance
HK1048263A1 (en) Medicaments that contain xenogenic oligo-or/and polyribonucleotides.
WO2004006866A3 (fr) Cibles therapeutiques antifongiques
UA32303A (uk) Спосіб лікування папіломатозу

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP NZ

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP NZ

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP